Results 21 to 30 of about 70,632 (244)
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]
Postgraduate Medicine, 2013 Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
exaly +3 more sources
Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1. [PDF]
Cancers (Basel), 2019 Janus kinases (JAKs) are found constitutively associated with cytokine receptors and are present in an inactive state prior to cytokine exposure. Activating mutations of JAKs are causative for a number of leukemias, lymphomas, and myeloproliferative diseases.
Liau NPD +6 more
europepmc +5 more sources
Untangle a Broken Heart via Janus Kinase 1. [PDF]
Circ Res, 2017 Protein homeostasis and quality control, as balanced by synthesis and degradation, is critical to cellular health and normal cardiac function. Similar to amyloid-related neurodegenerative diseases, the familial forms of amyloid cardiomyopathy are characterized by protein aggregate accumulation in cardiomyocytes.
Gao C, Wang Y.
europepmc +4 more sources
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib [PDF]
Clinical, Cosmetic and Investigational DermatologyYingzhi Luo,1,* Jian Wu,2,* Xingyun Zhao,1,* Ping Yang,1 Yunmi Qiu,1 Liming Wu,1 Jianbo Zhong1 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang ...
Luo Y +6 more
doaj +2 more sources
miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1. [PDF]
Oncol Lett, 2021 Endometrial cancer (EC) is a multi-factorial disease of which pathogenesis has not been fully elucidated. The function and underlying mechanism of microRNA-20a-5p (miR-20a-5p) in EC remain poorly understood. The present study aimed to analyze the association between miR-20a-5p expression and the clinicopathological characteristics of patients with EC ...
He Y, Ma H, Wang J, Kang Y, Xue Q.
europepmc +4 more sources
Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo. [PDF]
Clin Cosmet Investig Dermatol, 2019 Vitiligo is an acquired autoimmune skin disorder. The often-visible lesions of vitiligo have a major impact on patients' quality of life and the results of the treatment regimens on offer are unsatisfactory, so there is a need for new therapeutic regimens.
Samaka RM, Basha MA, Menesy D.
europepmc +4 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011 Review on JAK1 (Janus kinase 1), with data on DNA, on the protein encoded, and where the gene is implicated.
Knoops, L, Hornakova, T, Renauld, JC
openaire +2 more sources
Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2022 SummaryThe use of Janus kinase inhibitors for the treatment of chronic inflammatory diseases is increasingly establishing itself as a treatment option for several indications. In order to make clinical use efficient, pharmacological knowledge of the JAK/STAT signaling pathway and the special features of the pharmacokinetics of the individual drugs is ...
Adina, Eichner, Johannes, Wohlrab
openaire +2 more sources
Loss of Cardiomyocyte Janus Kinase 1 (Jak1) Causes Cardiomyopathy
Journal of Molecular and Cellular Cardiology PlusArasakumar Subramani +4 more
doaj +2 more sources